SCHEMBL7174850

SCHEMBL7174850

NS(=O)(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CA1 P00915 16/20 0.45
CA2 P00918 16/20 0.45
THRB P10828 1/20 0.41
STS P08842 1/20 0.38
F2 P00734 2/20 0.34
PRSS1 P07477 2/20 0.34
PRSS2 P07478 2/20 0.34
PRSS3 P35030 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27677621 0.79 THRB (0.46) CA1CA2THRBSTSF2
SCHEMBL28064218 0.78 THRB (0.45) CA1CA2THRBSTSF2
SCHEMBL27712919 0.78 THRB (0.45) CA1CA2THRBSTSF2
Potassium Ion SCHEMBL27498497 0.76 THRB (0.43) CA1CA2THRBF2PRSS1
SCHEMBL22322503 0.76 THRB (0.43) CA1CA2THRBF2PRSS1
SCHEMBL29066797 0.76 THRB (0.43) CA1CA2THRBF2PRSS1
SCHEMBL27641982 0.76 THRB (0.43) CA1CA2THRBF2PRSS1
SCHEMBL7182154 0.75 CA1 (0.37) CA1CA2
SCHEMBL16505929 0.75 THRB (0.42) CA1CA2THRBF2PRSS1
SCHEMBL11743004 0.72 CA1 (0.33) CA1CA2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US claimed
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US disclosed